Cellectar Biosciences (CLRB) Non-Current Debt (2010 - 2020)

Cellectar Biosciences (CLRB) posted Non-Current Debt of $184000.0 for Q3 2020, little changed sequentially from $184000.0 in Q2 2020.

Cellectar Biosciences (CLRB) Non-Current Debt (2010 - 2020) Analysis & Trends

Cellectar Biosciences has reported Non-Current Debt for 8 years, with the latest figure at $184000.0 in Q3 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $184000.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $184000.0 (changed N/A YoY) and the FY2015 annual result came in at $86632.0, down 73.75% from the prior year.
Non-Current Debt held at $184000.0 in Q3 2020 per CLRB's latest filing, from $184000.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $184000.0 in Q2 2020 and troughed at $24885.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.40 Bn	131.54 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.13 Bn	78.13 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.58 Bn	60.40 Bn	1.37 Bn	-
4	Moderna	58.23 Bn	53.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.61 Bn	28.30 Bn	992.69 Mn	-
7	BioNTech SE	27.97 Bn	9.58 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	8.96 Bn
10	Cellectar Biosciences	6.73 Mn	6.73 Mn	-	-

Download Data